SEEGENE AND SHIMADZU AGREE TO JOIN MULTI-PATHOGEN TESTS AND PLATFORM FOR COMBINED ANALYTICS SOLUTION

Seegene, Inc. and Shimadzu Corporation today announced a strategic partnership to combine Seegene's Seeplex(R) multi-pathogen tests with Shimadzu's MultiNA(1) analytical platform. Under terms of the deal, Shimadzu and Seegene will collaborate on integrating the Seeplex polymerase chain reaction-based tests with Shimadzu's MultiNA high-speed electrophoresis system to provide a highly sensitive, high-throughput multi-pathogen detection and analysis solution.

"This strategic agreement reinforces our plan to bring solutions, and not only products, to our customers," said Dr. Jong-Yoon Chun, Founder and Chief Executive Officer, Seegene. "Shimadzu's MultiNA is outstanding in the market for electrophoresis analysis and a perfect match for the Seeplex family of multi-pathogen tests."

"Seegene's novel multi-pathogen detection test working with Shimadzu's next-generation electrophoresis systems creates an unparalleled screening platform for laboratories around the world," said Yoshiyuki Togawa, General Manager, Shimadzu. "Seeplex tests running on MultiNA is the fast, accurate and efficient way for laboratories to screen for the most rampant and debilitating pathogens infecting people around worldwide."

Shimadzu's MultiNA is a microchip electrophoresis system that quickly and easily performs DNA and RNA nucleic acid size confirmation and quantification. The system uses microchip technology to conduct fully automated high-speed electrophoresis separation, and fluorescence detection to perform high-sensitivity analysis.

Seeplex tests are based on a breakthrough multiplexing PCR technology capable of detecting multiple pathogens in a single tube. Seeplex-based tests deliver maximum specificity, reproducibility and sensitivity and can be applied to a broad range of molecular diagnostics, including human, animal, plant and microorganism. Currently, Seegene's Seeplex multi-pathogen detection tests offer labs worldwide simple, cost-effective and comprehensive screening for STDs, respiratory viruses, human papillomaviruses, sepsis and pneumonia.

(1) MultiNA is Research Use Only.

-ends-

About Seegene

Seegene, Inc. is pioneering the field of multi-pathogen testing. Seegene applies its novel and proprietary Seeplex system utilizing "DPO (Dual Priming Oligo)" and "ACP (Annealing Control Primer)" to create multi-pathogen tests delivering maximum specificity, reproducibility and sensitivity. With over 360 citations and several patents and patents pending, Seegene has been offering advanced molecular diagnostics services to over 1,200 major global institutes in more than 30 countries. Seegene is actively working with both the scientific and OEM business community. Seegene's mission is to integrate Seeplex with disease diagnostics to provide a new guideline for effectively treating patients. Seegene was founded in 2000 and is based in Rockville, MD and Seoul, Korea. For more information please visit www.seegene.com.

About Shimadzu

Shimadzu Corporation develops and manufactures analytical and monitoring equipment for science laboratories worldwide. Its products include imaging systems for medical diagnosis such as ultrasound systems and mobile X-ray systems, as well as spectrophotometers and chromatography systems for the life science sector. Founded in 1975, Shimadzu Scientific Instruments (SSI) is the North American arm of the analytical instruments manufacturer. For more information about Shimadzu’s extensive line of laboratory offerings, please visit www.shimadzu.com.

Note: "Safe Harbor" Statement Under the Private Securities Litigation Reform Act of 1995. Some of the statements in this release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than those of historical facts included herein, including those related to the company's financial outlook, goals, business strategy, projected plans and objectives of management for future operations, new order trends and liquidity are forward-looking statements.

Such "forward-looking statements" involve unknown risks and uncertainties that may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements, expressed or implied by such forward-looking statements. Factors such as general economic and business conditions, availability of required capital for Shimadzu Corporation and the Fred Hutchinson Cancer Research Center, and its affiliates, continued government support and funding for key space and defense programs, the financial condition of major customers, product performance, market acceptance of products, services and technologies, consumer demand, and dependence upon long-term contracts with commercial and government customers may impact the company's revenues, expenses, profit and cash flow from period to period. These factors and others related to the company's business are described in further detail in the company's SEC filings, including its Form 10-K, as amended, for the year ended December 31, 2007. Shimadzu assumes no obligation to update any such forward-looking information.